1. Home
  2. MTA vs EOLS Comparison

MTA vs EOLS Comparison

Compare MTA & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTA
  • EOLS
  • Stock Information
  • Founded
  • MTA 1983
  • EOLS 2012
  • Country
  • MTA Canada
  • EOLS United States
  • Employees
  • MTA N/A
  • EOLS N/A
  • Industry
  • MTA
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MTA
  • EOLS Health Care
  • Exchange
  • MTA Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • MTA 398.8M
  • EOLS 412.0M
  • IPO Year
  • MTA N/A
  • EOLS 2018
  • Fundamental
  • Price
  • MTA $5.47
  • EOLS $7.63
  • Analyst Decision
  • MTA Hold
  • EOLS Strong Buy
  • Analyst Count
  • MTA 1
  • EOLS 5
  • Target Price
  • MTA $4.50
  • EOLS $21.25
  • AVG Volume (30 Days)
  • MTA 529.1K
  • EOLS 2.2M
  • Earning Date
  • MTA 08-14-2025
  • EOLS 08-05-2025
  • Dividend Yield
  • MTA N/A
  • EOLS N/A
  • EPS Growth
  • MTA N/A
  • EOLS N/A
  • EPS
  • MTA N/A
  • EOLS N/A
  • Revenue
  • MTA $8,167,999.00
  • EOLS $277,941,000.00
  • Revenue This Year
  • MTA $120.74
  • EOLS $14.01
  • Revenue Next Year
  • MTA $54.89
  • EOLS $29.46
  • P/E Ratio
  • MTA N/A
  • EOLS N/A
  • Revenue Growth
  • MTA 70.70
  • EOLS 17.15
  • 52 Week Low
  • MTA $2.45
  • EOLS $5.71
  • 52 Week High
  • MTA $5.60
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • MTA 81.00
  • EOLS 48.91
  • Support Level
  • MTA $4.09
  • EOLS $7.39
  • Resistance Level
  • MTA $5.60
  • EOLS $7.70
  • Average True Range (ATR)
  • MTA 0.21
  • EOLS 0.39
  • MACD
  • MTA 0.11
  • EOLS 0.17
  • Stochastic Oscillator
  • MTA 91.39
  • EOLS 84.91

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: